Cyclacel Pharmaceuticals, Inc. (CYCC)
NASDAQ: CYCC · Real-Time Price · USD
0.505
-0.122 (-19.44%)
At close: Nov 4, 2024, 4:00 PM
0.510
+0.005 (1.01%)
After-hours: Nov 4, 2024, 7:59 PM EST
Cyclacel Pharmaceuticals Revenue
Cyclacel Pharmaceuticals had revenue of $4.00K in the quarter ending June 30, 2024, a decrease of -98.93%. This brings the company's revenue in the last twelve months to $80.00K, down -78.55% year-over-year. In the year 2023, Cyclacel Pharmaceuticals had annual revenue of $420.00K.
Revenue (ttm)
$80.00K
Revenue Growth
-78.55%
P/S Ratio
14.15
Revenue / Employee
$6,667
Employees
12
Market Cap
996.97K
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
LogicMark | 9.74M |
SciSparc | 2.88M |
Akanda | 2.51M |
Elevai Labs | 2.47M |
60 Degrees Pharmaceuticals | 441.26K |
Catheter Precision | 436.00K |
CYCC News
- 11 days ago - Cyclacel Pharmaceuticals Announces That Nasdaq Granted an Extension to Regain Compliance With the Equity Standard Rule - GlobeNewsWire
- 12 days ago - Cyclacel Pharmaceuticals Reports New Clinical Data from Ongoing, Phase 2 Study of Oral Fadraciclib at the 2024 EORTC-NCI-AACR Symposium - GlobeNewsWire
- 26 days ago - Cyclacel Pharmaceuticals to Present New Clinical Data From Phase 2 Study of Oral Fadraciclib at the 2024 EORTC-NCI-AACR Symposium - GlobeNewsWire
- 5 weeks ago - Cyclacel Pharmaceuticals Announces Completion of Enrollment in the Biomarker-Enriched Patient Cohort of Its Phase 2 Study - GlobeNewsWire
- 2 months ago - Cyclacel Pharmaceuticals Announces Participation at the H.C. Wainwright 26th Annual Global Investment Conference - GlobeNewsWire
- 2 months ago - Cyclacel Pharmaceuticals Confirms It Has Filed an Appeal to Nasdaq Staff Delisting Letter - GlobeNewsWire
- 2 months ago - Cyclacel Pharmaceuticals, Inc. (CYCC) Q2 2024 Earnings Call Transcript - Seeking Alpha
- 3 months ago - Cyclacel Pharmaceuticals to Release Second Quarter 2024 Financial Results - GlobeNewsWire